Taiwan's National Health Insurance Administration (NHIA) has decided to cover an expensive but effective gene therapy for a rare disease aromatic L-amino acid decarboxylase (AADC) deficiency.
If you are already a subscriber
OR sign-up for a trial access here
Note that your comment may be edited or removed in the future, and that your comment may appear alongside the original article on websites other than this one.
There are no comments submitted yet. Do you have an interesting opinion? Then be the first to post a comment.
more »